Warning

Contents supplied STERILE using an ethylene oxide (EO) process. Do not use if sterile barrier is damaged. If damage is found, call your Boston Scientific representative. For single use only. Do not reuse, reprocess or resterilise. Reuse, reprocessing or resterilisation may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness or death. Reuse, reprocessing or resterilisation may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient. After use, dispose of product and packaging in accordance with hospital, administrative and/or local government policy.

Intended Use/Indications For Use

The Agile Esophageal Partially Covered and Fully Covered Stent Systems is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and/or extrinsic malignant tumour, and occlusion of concurrent esophageal fistulas.

Contraindications

The Agile Esophageal Partially Covered Stent System and Agile Esophageal Fully Covered Stent Systems are contraindicated for:

- Placement in esophageal strictures caused by benign tumours, as the long-term effects of the stent in the esophagus are unknown.
- Placement in strictures that cannot be dilated enough to pass the gastroscope or the delivery system.
- Placement of the proximal end of stent within 2cm of the cricopharyngeal muscle.
- Placement in an esophago-jejunostomy (following gastrectomy), as peristalsis and altered anatomy may displace stent.
- Placement in necrotic chronically bleeding tumours, if bleeding is active at the time of placement.
- Placement in polyoid lesions.
- Those patients for whom endoscopic techniques are contraindicated.
- Any use other than those specifically outlined under indications for use.
- Placement in patients who have an underlying bleeding diathesis.
Warnings and Cautions

- The risk of perforation and erosion into adjacent vascular structures or aortoesophageal and arterioesophageal fistulas may be increased with pre- or post-operative chemotherapy and radiation, longer implantation times, aberrant anatomy, and/or mediastinal contamination or inflammation.

- As perforation is a known risk, the stent should be used with caution and only after careful consideration in patients who are:
  - Undergoing radiation therapy and/or chemotherapy
  - In advanced stages of cancer

- The Agile Esophageal Partially Covered Stent System and Agile Esophageal Fully Covered Stent System should be used with caution and only after careful consideration in patients with:
  - Strictures exceeding 12cm in length
  - Significant preexisting pulmonary or cardiac disease

- This device contains nickel, which may cause an allergic reaction in individuals with nickel sensitivity.

- Stent is considered to be a permanent device. Once stent placement is permanently achieved, stent removal or repositioning is not recommended.

- Visually inspect the system for any signs of damage. DO NOT USE if the system has any visible signs of damage. Failure to observe this warning may result in patient injury.

Adverse Events

The potential adverse effects associated with esophageal stent placement may include:

- Bleeding
- Perforation
- Pain
- Aspiration
- Stent migration
- Tumour ingrowth through uncovered portion of stent
- Tumour overgrowth around stent ends
- Foreign body sensation
- Food bolus impaction
- Reflux
- Esophagitis
- Edema
- Ulceration
- Fever
- Infection
- Sepsis
- Septicemia
- Recurrent dysphagia
- Fistula formation
- Tracheal compression/obstruction (or acute airway compression)
- Hematemesis
- Death (other than that due to normal disease progression)
- Stent fracture

Possible post stent complications:

- Sensitivity to the metal component of the stent
- Mediastinitis
- Aspiration
- Intestinal obstruction (secondary to stent migration)
- Granulation tissue around stent ends
- Aorto and arterioesophageal fistula
- Erosion or perforation of stent into adjacent vascular strictures

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.